Health Catalyst stock (US42226A1079): Q1 beat with EPS of $0.02, revenue $70.76M

Health Catalyst reported Q1 2026 earnings on May 11, beating estimates with EPS of $0.02 versus $0.01 expected and revenue of $70.76 million above $69.24 million consensus.

Health Catalyst Inc released its first quarter 2026 earnings on May 11, 2026, posting adjusted EPS of $0.02, surpassing analyst consensus of $0.01 by $0.01. Quarterly revenue reached $70.76 million, topping the expected $69.24 million, according to MarketBeat as of May 2026. The results highlight ongoing execution in healthcare data analytics amid a challenging market for the NASDAQ-listed firm.

As of: 14.05.2026

By the editorial team – specialized in equity coverage.

At a glance

• Name: Health Catalyst Inc
• Sector/industry: Healthcare IT / Data Analytics
• Headquarters/country: United States
• Core markets: US healthcare providers
• Key revenue drivers: Software subscriptions, analytics services
• Home exchange/listing venue: Nasdaq (HCAT)
• Trading currency: USD

Health Catalyst: core business model

Health Catalyst provides data and analytics technology to healthcare organizations, enabling them to improve clinical, financial, and operational performance. The platform combines technology, professional services, and analytics to drive value-based care outcomes. Core offerings include the Health Catalyst Analytics Platform and related stewardship services, deployed across hospitals and health systems in the US.

For the full year 2025, annual revenue stood at $311.14 million with net income of -$177.97 million, as reported in Q1 2026 filings, according to MarketBeat as of May 2026. The company remains unprofitable on a GAAP basis but shows progress in adjusted metrics.

Main revenue and product drivers for Health Catalyst

Revenue primarily stems from subscription-based software and professional services. In Q1 2026, the $70.76 million top line reflected strength in technology sales and analytics contracts with US providers. Key drivers include demand for data interoperability solutions amid regulatory pushes for healthcare digitization.

Trailing twelve months EPS was -$2.54, with analysts projecting improvement to -$0.23 for the next year from -$0.28, per MarketBeat as of May 2026. Growth hinges on expanding contracts with large health systems.

Industry trends and competitive position

The US healthcare IT sector benefits from rising data volumes and AI integration needs. Health Catalyst competes with firms like Optum and Cerner in analytics, focusing on mid-sized providers. Its scalable platform positions it well for value-based care shifts mandated by CMS regulations.

Why Health Catalyst matters for US investors

As a Nasdaq-listed pure-play in healthcare data, Health Catalyst offers exposure to the $4 trillion US healthcare market's digital transformation. With listings on major US exchanges, it provides retail investors direct access to innovations addressing payer-provider data challenges.

Conclusion

Health Catalyst's Q1 2026 earnings beat underscores resilience in healthcare analytics demand, with revenue and EPS exceeding forecasts. While trailing profitability challenges persist, projected EPS improvements signal potential stabilization. Investors track execution on contracts and market expansion amid sector digitization trends.

Disclaimer: This article does not constitute investment advice. Stocks are volatile financial instruments.